Advances in the treatment of liver tumors

Current Problems in Surgery

Volumn 39, Issue 5, 2002, Pages 461-571

  Curley Jr, Steven A ^a   Cusack Jr, James C ^a   Tanabe, Kenneth K ^a   Ellis, Lee M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACLARUBICIN; ALPHA INTERFERON; ANGIOGENIN; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ENDOSTATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IODINATED POPPYSEED OIL; IRINOTECAN; MITOMYCIN C; ONYX 015; OXALIPLATIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SU 6668; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; [3 METHYL 1 [[1 OXO 3 PHENYL 2 [(PYRAZINYLCARBONYL)AMINO]PROPYL]AMINO]BUTYL]BORONIC ACID; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CATHETER ABLATION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; ELECTROCOAGULATION; GENE MUTATION; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; HYPERTHERMIC THERAPY; LAPAROSCOPIC SURGERY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER RESECTION; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE COMPLICATION; REVIEW; STAPLER; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION; VOMITING; BRACHYTHERAPY; COLON TUMOR; DIATHERMY; GENETICS; IMMUNOLOGY; LIVER; LIVER TUMOR; METASTASIS; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PORTAL VEIN; VIRUS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIATHERMY; EMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PORTAL VEIN; VIRUSES;

EID: 0036072659     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/msg.2002.122810     Document Type: Article

References (269)

1. A historic perspective of liver surgery for tumors at the end of the millennium
2. Surgical treatment of tumor of the liver with report of a case
3. Etudes anatomiques et chirurgales
4. Hepatic metastases from colorectal cancer: Preoperative detection and assessment of resectability with helical CT
5. Dual phase helical CT versus portal venous phase CT for the detection of colorectal liver metastases: Correlation with intra-operative sonography, surgical and pathological findings
6. Small nodule detection in cirrhotic livers: Evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver
7. Radiologic diagnosis of hepatocellular carcinoma
8. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America
9. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis
10. Contrast-enhanced, wide-band harmonic gray scale imaging of hepatocellular carcinoma: Correlation with helical computed tomographic findings
11. Microbubble contrast agents: A new era in ultrasound
12. Gene transfection and drug delivery
13. Intraoperative ultrasonic examination for hepatectomy
14. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound
15. Laparoscopic radiofrequency of hepatocellular carcinoma (HCC) in liver cirrhosis
16. Improved survival after resection of colorectal liver metastases
17. What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease?
18. Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer
19. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases
20. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma
21. Surgical management of hepatocellular carcinoma
22. Preoperative estimation of surgical risk of hepatectomy in cirrhotic patients
23. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy
24. Hepatic phenylalanine metabolism measured by the [13C]phenylalanine breath test
25. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests
26. The hippurate ratio as an indicator of functional hepatic reserve for resection of hepatocellular carcinoma in cirrhotic patients
27. Preoperative assessment of residual hepatic functional reserve using 99mTc-DTPA-galactosyl-human serum albumin dynamic SPECT
28. Assessment of hepatic blood flow by PET with 15O water: Correlation between per-rectal portal scintigraphy with 99Tc(m)-pertechnetate and scintigraphy with 99Tc(m)-GSA
29. Hepatocellular carcinoma
30. Hepatocellular carcinoma: An overview
31. Hematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies
32. Primary liver cancer in Japan: Clinicopathologic features and results of surgical treatment
33. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma
34. Liver resection for colorectal metastases
35. Hepatectomy for noncolorectal liver metastases
36. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection
37. Patient selection for hepatic resection of colorectal metastases
38. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: Long-term results
39. Survival after resection of multiple hepatic colorectal metastases
40. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer
41. Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years
42. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value
43. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma
44. Hepatocellular carcinoma with biliary tumor thrombi: Aggressive operative approach after appropriate preoperative management
45. Simplified inflow control using stapling devices for major hepatic resection
46. Vascular endostapler as aid to hepatic vein control during hepatic resections
47. Useful stapling techniques in liver surgery
48. A prospective analysis of staging laparoscopy in patients with primary and secondary hepatobiliary malignancies
49. Hand-assisted laparoscopic liver resection: Lessons from an initial experience
50. Early experience with laparoscopic approach for solid liver tumors: Initial 16 cases
51. Laparoscopic liver resections: A feasibility study in 30 patients
52. New frontiers in liver surgery: Two-stage liver surgery for the management of advanced metastatic liver disease
53. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors
54. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation
55. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma
56. Repeat hepatic resection as effective treatment for recurrent colorectal liver metastases
57. Repeat hepatectomy for colorectal metastases
58. Aggressive surgical approach to recurrent tumors after hepatectomy for metastatic spread of colorectal cancer to the liver
59. Repeat hepatectomy for colorectal liver metastases: A worthwhile operation?
60. Repeat liver resection for hepatocellular carcinoma
61. Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: Repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer
62. Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study
63. Tolerance of the liver to intermittent pringle maneuver in hepatectomy for liver tumors
64. Continuous versus intermittent portal triad clamping for liver resection: A controlled study
65. Hepatic resection with vascular isolation and routine supraceliac aortic clamping
66. Total vascular exclusion of the liver for the resection of lesions in contact with the vena cava or the hepatic veins
67. Is radical hepatic surgery safe?
68. Hepatic resections in normothermic ischemia
69. Total vascular exclusion for hepatic resection in cirrhotic patients: Application of venovenous bypass
70. Surgical and anesthetic management of patients undergoing major hepatectomy using total vascular exclusion
71. Liver resection without total vascular exclusion: Hazardous or beneficial? An analysis of our experience
72. Preoperative portal vein embolization for hepatocellular carcinoma
73. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: A preliminary report
74. Extended hepatic resection: A 6-year retrospective study of risk factors for perioperative mortality
75. Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations
76. Extended hepatectomy in hepatobiliary malignancies with and without preoperative portal vein embolization
77. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors
78. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization
79. Embolization of portal vein branches induces hepatocyte replication in swine: A potential step in hepatic gene therapy
80. Calculation of child and adult standard liver volume for liver transplantation
81. The significance of measuring liver volume using computed tomographic images before and after hepatectomy
82. Hepatic metastases from colorectal cancer: Influence of hepatic volumetric analysis on surgical decision making
83. Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinoma
84. Right trisegment portal vein embolization for biliary tract carcinoma: Technique and clinical utility
85. Preoperative portal vein embolization for extension of hepatectomy indications
86. Preoperative portal vein embolization: An audit of 84 patients
87. Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol: A clinical study
88. New possibilities for major liver surgery in patients with Klatskin tumors or primary hepatocellular carcinoma: An old problem revisited
89. Portal vein embolization: Utility for inducing left hepatic lobe hypertrophy before surgery
90. Percutaneous transhepatic portal embolization using newly devised catheters: Preliminary report
91. Radical operation after portal embolization for tumor of hilar bile duct
92. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization
93. Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers: A preliminary report
94. Resultats carcinologiques a long terme des hepatectomies realisee apres embolisation portal selective
95. Portal vein embolization: Rationale, technique and future prospects
96. Laser hyperthermia and radiofrequency ablation of hepatic lesions
97. Temperature range and selective sensitivity of tumors to hyperthermia: A critical review
98. Hyperthermia
99. Characteristics of heat transfer and determination of temperature gradient and viability threshold during radiofrequency fulguration of isolated perfused canine right ventricle
100. Laser-tissue interactions: Considerations for cardiovascular applications
101. A morphological study of cooling rate response in normal and neoplastic human liver tissue: Cryosurgical implications
102. Hyperthermia in cancer therapy: Where are we today and where are we going?
103. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases
104. Ablation of liver tumors using percutaneous RF therapy
105. Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: Results of a pilot clinical trial
106. Clinical results of radiofrequency hyperthermia for malignant liver tumors
107. Hepatic ablation with use of radio-frequency electrocautery in the animal model
108. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients
109. Radiofrequency ablation of malignant liver tumors in 304 patients
110. Laparoscopically guided bipolar radiofrequency ablation of areas of porcine liver
111. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis
112. The role of blood flow in hyperthermia
113. Large blood vessel cooling in heated tissues: A numerical study
114. Hepatic inflow occlusion increases the efficacy of interstitial laser-induced thermotherapy in rat
115. Radiofrequency ablation of malignant liver tumors
116. Radiofrequency thermal ablation of hepatic metastases
117. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors
118. Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications
119. Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors
120. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year
121. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases
122. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases
123. Radiofrequency ablation (RFA) of liver tumors: Assessment of therapeutic response and complications
124. Hepatocellular carcinoma recurrence after percutaneous ablation therapy: Helical CT patterns
125. Percutaneous ablation of liver malignancies: Imaging evaluation of treatment response
126. Comparison between color power Doppler ultrasound with echo-enhancer and spiral computed tomography in the evaluation of hepatocellular carcinoma vascularization before and after ablation procedures
127. The role of PET scanning in radiofrequency ablation of liver metastasis from colorectal cancer
128. Contribution of FDG positron emission tomography in the evaluation of the treatment of liver metastasis using radiofrequency ablation
129. Technology for in situ ablation by laparoscopic and image-guided interstitial laser hyperthermia
130. Interstitial laser thermotherapy in the treatment of colorectal liver metastases
131. Laser-tissue interactions. Photochemical, photothermal, and photomechanical
132. Optical properties of native and coagulated human liver tissue and liver metastases in the near infrared range
133. Interstitial laser-induced thermotherapy: Influence of carbonization on lesion size
134. Interstitial laser thermotherapy: Comparison between bare fibre and sapphire probe
135. Heat-resistant cylindrical diffuser for interstitial laser coagulation: Comparison with the bare-tip fiber in a porcine liver model
136. Feedback interstitial diode laser (805 nm) thermotherapy system: Ex vivo evaluation and mathematical modeling with one and four-fibers
137. Importance of eliminating portal flow to produce large intrahepatic lesions with interstitial laser coagulation
138. Ultrasound imaging of thermal therapy in in vitro liver
139. MRI guidance of infra-red laser liver tumour ablations, utilizing an open MRI configuration system: Technique and early progress
140. MR systems for image-guided therapy
141. MRI of laser-induced interstitial thermal injury in an in vivo animal liver model with histologic correlation
142. Temperature monitoring of interstitial thermal tissue coagulation using MR phase images
143. Colorectal liver metastases: Alternatives to resection
144. Interstitial laser photocoagulation under ultrasound guidance of liver tumors: Results in 104 treated patients
145. Treatment of hepatocellular carcinoma by percutaneous laser hyperthermia
146. Hepatocellular carcinoma: Long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization
147. Percutaneous MR imaging-guided laser-induced thermotherapy metastases
148. Microwave surgery: Hepatectomy using a microwave tissue coagulator
149. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma
150. Microwave coagulation therapy for hepatocellular carcinoma
151. CT-guided treatment of ultrasonically invisible hepatocellular carcinoma
152. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation
153. Effect of a microwave coagulator on implanted liver neoplasms in rats
154. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy
155. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal
156. Neo-adjuvant therapy improves resectability rates for colorectal liver metastases
157. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma
158. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma
159. Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma
160. The value of postoperative hepatic arterial infusion following curative liver resection
161. Adjuvant regional chemotherapy after hepatic resection for colorectal metastases
162. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
163. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
164. Feasibility of adjuvant hepatic arterial infusion (HAI) of chemotherapy following radiofrequency ablation (RFA) ± resection in patients with hepatic metastasis from colorectal cancer
165. Apoptosis induced by anticancer drugs
166. Apoptosis: Its significance in cancer and cancer therapy
167. Mechanisms and genes of cellular suicide
168. Inherent increase of apoptosis in liver tumors: Implications for carcinogenesis and tumor regression
169. Apoptosis: Its role in the development of malignancies and its potential as a novel therapeutic target
170. p53 Deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage
171. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival
172. A genetic model for colorectal tumorigenesis
173. p53, the cellular gatekeeper for growth and division
174. A model for p53-induced apoptosis
175. Apoptosis in cancer therapy: Crossing the threshold
176. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB
177. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
178. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex
179. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation
180. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis
181. Two TNF receptors
182. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
183. Chemosensitization of colorectal cancer cells by expression of the NF-κB super-repressor IκBα
184. Chemosensitization of human fibrosarcoma xenografts following adenoviral-mediated transfer of the NF-κB super-repressor IκBα gene
185. Proteasome inhibitors: A novel class of potent and effective antitumor agents
186. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
187. Structure and functions of the 20S and 26S proteasomes
188. New insights into proteasome function: From archaebacteria to drug development
189. How proteolysis drives the cell cycle
190. Inhibition of NF-kappa B activation in vitro and in vivo: Role of 26S proteasome
191. Inducible chemoresistance to 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation
192. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition
193. Replicating viruses as selective cancer therapeutics
194. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
195. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector
196. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil
197. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
198. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
199. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
200. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
201. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
202. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
203. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
204. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
205. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
206. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
207. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors
208. Intra-arterial administration of a replication-selective adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility, and biological activity
209. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
210. Strategies in the development of recombinant vaccines for colon cancer
211. A mutant vaccinia virus with improved tumor selectivity
212. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy
213. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice
214. Conditionally replicating herpes vectors for cancer therapy
215. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant
216. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
217. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus
218. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector
219. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma
220. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect"
221. The "bystander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice
222. Clinical strategies for cancer treatment: The role of drugs
223. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
224. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus
225. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
226. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses
227. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model
228. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells
229. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
230. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
231. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma
232. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer
233. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
234. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth
235. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions
236. Regulation of angiogenesis via vascular endothelial growth factor receptors
237. Molecular determinants in the biology of liver metastasis
238. Angioarchitecture and blood supply of micro- and macrometastases in human livers: An anatomic-pathological investigation using injection techniques
239. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue
240. Histologic growth patterns of metastatic carcinomas of the liver
241. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
242. Role of the tumor microenvironment in mediating response to anti-angiogenic therapy
243. Liver regeneration: Molecular mechanisms of growth control
244. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression
245. Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases
246. Characterization of insulin-like growth factor I receptors in human colon cancer
247. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1
248. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic
249. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis
250. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing
251. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing
252. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing
253. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
254. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
255. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
256. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
257. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival
258. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells
259. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
260. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
261. Angiostatin and endostatin: Endogenous inhibitors of tumor growth
262. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer
263. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
264. Zinc-binding of endostatin is essential for its antiangiogenic activity
265. Endostatin induces endothelial cell apoptosis
266. Mouse endostatin inhibits the formation of lung and liver metastases
267. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101
268. Efficacy results of a Phase I/II study of SU5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients from a Phase III study of Irinotecan (C)/F/L or F/L alone in the untreated metastatic colorectal cancer
269. Bevacizuma (BV) + chemotherapy (CT) may improve survival in metastatic colorectal cancer subjects with unfavorable prognostic indicators